Trial Profile
Treatment of systemic effects in patients with COPD.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2023
Price :
$35
*
At a glance
- Drugs Acetylcysteine (Primary) ; Rosuvastatin (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacodynamics; Therapeutic Use
- Sponsors AstraZeneca
- 01 Jun 2011 New trial record